6th Annual Multicultural Pharmaceutical Marketing, Media, & Public Relations

Featured Conference 6th Annual Multicultural Pharmaceutical Marketing, Media, & Public Relations March 17 - 18, 2005 • Sheraton Woodbridge Place - Iselin,...

6th Annual Sample Accountability

Structure State and Federally Compliant Sample Programs to Minimize Risk, Monitor Your Sales Force and Reconcile Inventories

The Pharma, Biotech and Device Colloquium

The Pharma, Biotech and Device Colloquium, June 6 - 9, 2004, on the Campus of Princeton University Announces Extraordinary Faculty.

4th Annual Pharmaceutical Contact Centers

Featured Conference 4th Annual Pharmaceutical Contact Centers January 27 - 28, 2005 • Philadelphia, PA Visit the conference website for...

CBI’s 8th Annual Forum on eMarketing for the Pharmaceutical Industry

Ensure Effective eCommunication with Physicians and Patients Using Innovative 2.0 and Online Approaches

6th Annual Forum on Continuing Medical Education (CME)

Comply with Guidelines and Standards to Maximize and Improve CME Activities


Obtaining real world effectiveness data about products in various patient populations critical for your company's success.

3rd Annual Conference on Patient Awareness, Recruitment and Retention for Clinical Trials

Ensure an Appropriate and Dedicated Population through Educational Campaigns and Innovative Participation Techniques for Domestic and International Trials

CBI’s Annual Recalls Summit

This conference provides the only platform for the industry to discuss critical topics regarding planning for, and navigating through, a product recall.

Reporting Drug Safety Research

There are several key areas that will be discussed and debated during this program, including Safety Data Analysis, a risk management framework for drug safety research, the FDA’s guidance document on Post-Marketing Risk Assessment, Good Pharmacovigilancve Practices & Pharmacoepidemiologic Assessment, strategies for effective data transparency and corporate image management, emerging technologies to streamline risk management in drug safety reporting and post-marketing surveillance and best practices in the analysis of this data as well as optimal methods of information delivery.
- Advertisement -